BioSpace News Archive

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses has released the Company’s 3Q2023 unaudited condensed interim consolidated Financial Statements.

G1 Therapeutics, Inc. announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast cancer from the Company’s Phase 2 trial will be presented in a poster session during the upcoming 2023 San Antonio Breast Cancer Symposium, held December 5th through 9th in San Antonio, TX.

Nascent Biotech, Inc. is pleased to announce the Company has been issued a patent from the Japanese Patent Office for its primary asset, Pritumumab.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).

Zilia, a medical technology company specializing in the non-invasive assessment of ocular biomarkers, announced today a significant advancement in the deployment of its groundbreaking technology set to transform the diagnosis and management of ocular diseases.

Enveric Biosciences today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.

Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) reported today interim data from an ongoing Phase 1 study designed to assess and compare the pharmacokinetic (PK) and early pharmacodynamic (PD) profile of current and several next generation compositions of its oral peptide platform (NCT05965167).

Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published in the journal CHEST show that the company’s Percepta Nasal Swab test determines lung cancer risk, with high accuracy, among people who currently smoke or have previously smoked and have lung nodules.

Through its leading imaging solutions and commitment to innovation, GE HealthCare remains at the forefront of leveraging deep learning, a subset of artificial intelligence, to benefit a multitude of clinicians and patients.

Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company”) is pleased to provide its unaudited financial results for the three- and six- month periods ended September 30, 2023. These filings and additional information regarding Britannia are available for review on SEDAR at www.sedar.com. All amounts are Canadian dollars unless otherwise stated.